CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Centessa Investors of a Lead Plaintiff Deadline of November 28, 2022

NEW YORK, Oct 31, 2022

The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022.

If you suffered a loss on your investment in Centessa, contact us about potential recovery by using the link below. There is no cost or obligation to you.

https://www.wongesq.com/pslra-1/centessa-class-action-lawsuit-loss-submission-form?prid=33129&wire=4

ABOUT THE ACTION: The class action against Centessa includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

DEADLINE: November 28, 2022

Aggrieved Centessa investors only have until November 28, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.